PMID- 28052368 OWN - NLM STAT- MEDLINE DCOM- 20171013 LR - 20181113 IS - 1365-2230 (Electronic) IS - 0307-6938 (Print) IS - 0307-6938 (Linking) VI - 42 IP - 3 DP - 2017 Apr TI - Synthesis and activity of the salicylic acid ester of bakuchiol in psoriasis-surrogate keratinocytes and skin substitutes. PG - 251-260 LID - 10.1111/ced.13024 [doi] AB - BACKGROUND: Topical retinoids are effective in retarding skin ageing and restoring homeostasis in skin conditions such as psoriasis. However their adverse effects (AEs), which include irritation (retinoid dermatitis), photosensitivity and teratogenicity, limit their use and patient compliance. Development of retinoid analogues with minimal AEs would allow a broader and more compliant use. AIM: To synthesise a novel molecule, bakuchiol salicylate (bakusylan), with a modulatory gene expression profile similar to retinoids, using as reference three prescription retinoids: tretinoin, tazarotene and adapalene. METHODS: We hypothesized that because bakuchiol salicylate has a structure entirely different from existing retinoids, there would be at least a partial uncoupling of AEs from the skin-normalizing activity of this retinoid. This hypothesis was tested at the transcriptional level in psoriatic cytokine-treated cultures of keratinocytes and organotypic skin substitutes, using DNA microarrays and custom PCR arrays. RESULTS: Evaluation of the gene expression profile of bakuchiol salicylate revealed elimination of several components of the retinoid-like proinflammatory response and teratogenic signature, without a substantial loss of normalizing potential. A possible mechanism of action, consisting of keratinocyte desensitization to psoriatic cytokine signalling through inhibition of the signal transducer and regulator of transcription (STAT)1/3/interferon inflammatory signal transduction axis was also identified. CONCLUSION: Bipartite materials obtained by merging two skin-active entities with specific, complementary bioactivities, such as bakuchiol and salicylic acid, may yield a new class of functional retinoids. CI - (c) 2017 British Association of Dermatologists. FAU - Ma, S AU - Ma S AD - Sunny BioDiscovery, Inc., Santa Paula, CA, USA. FAU - Gobis, K AU - Gobis K AD - Department of Organic Chemistry, Medical University of Gdansk, Gdansk, Poland. FAU - Swindell, W R AU - Swindell WR AD - University of Ohio, Athens, OH, USA. FAU - Chaudhuri, R AU - Chaudhuri R AD - Sytheon, Boonton, NJ, USA. FAU - Bojanowski, R AU - Bojanowski R AD - Sunny BioDiscovery, Inc., Santa Paula, CA, USA. AD - Polish Academy of Sciences, Institute of Oceanology, Sopot, Poland. FAU - Bojanowski, K AU - Bojanowski K AD - Sunny BioDiscovery, Inc., Santa Paula, CA, USA. LA - eng GR - R43 AR062935/AR/NIAMS NIH HHS/United States PT - Journal Article DEP - 20170104 PL - England TA - Clin Exp Dermatol JT - Clinical and experimental dermatology JID - 7606847 RN - 0 (Cytokines) RN - 0 (Phenols) RN - 0 (Retinoids) RN - 0 (Salicylates) RN - OT12HJU3AR (bakuchiol) SB - IM MH - Cells, Cultured MH - Cytokines/metabolism MH - Gene Expression MH - Gene Expression Profiling MH - Humans MH - Keratinocytes/*drug effects/metabolism MH - Oligonucleotide Array Sequence Analysis/methods MH - Phenols/chemical synthesis/*chemistry/pharmacology MH - Polymerase Chain Reaction/methods MH - Psoriasis/*drug therapy/genetics MH - Retinoids/adverse effects MH - Salicylates/chemical synthesis/*chemistry/pharmacology MH - Skin, Artificial PMC - PMC5600152 MID - NIHMS828611 EDAT- 2017/01/05 06:00 MHDA- 2017/10/14 06:00 PMCR- 2018/04/01 CRDT- 2017/01/05 06:00 PHST- 2016/03/31 00:00 [accepted] PHST- 2017/01/05 06:00 [pubmed] PHST- 2017/10/14 06:00 [medline] PHST- 2017/01/05 06:00 [entrez] PHST- 2018/04/01 00:00 [pmc-release] AID - 10.1111/ced.13024 [doi] PST - ppublish SO - Clin Exp Dermatol. 2017 Apr;42(3):251-260. doi: 10.1111/ced.13024. Epub 2017 Jan 4.